Advertisement

Topics

Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma

08:00 EDT 23 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
- First ACTR Combination Therapy Under Unum’s Collaboration with Seattle Genetics – - Company Plans to Initiate Patient Dosing in a Multi-center, Phase 1 Trial in Q1 2018 – Unum Therapeutics Inc....

Other Sources for this Article

Unum Therapeutics Inc.
Jeff Michaels, +1-617-843-3820
Corporate_Communications@unumrx.com

NEXT ARTICLE

More From BioPortfolio on "Unum Therapeutics Announces Active Investigational New Drug (IND) Application for ACTR087 in Combination with SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...